CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BMS-986322 PlaceboWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2818 famotidine Wiki 1.00
drug301 BMS-986322 Wiki 1.00
drug726 Data record Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D000230 Adenocarcinoma NIH 1.00

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986322 in Healthy Participants Including an Open-label Assessment of Food and pH Effects on Relative Bioavailability of BMS-986322

A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy Participants compared to a placebo. The study also assesses how BMS-986322 affects the body with food and its acidity levels.

NCT04175925 Healthy Participants Drug: BMS-986322 Other: BMS-986322 Placebo Drug: famotidine

Primary Outcomes

Measure: Incidence of Death

Time: up to 12 months

Measure: Incidence of Adverse Effects (AEs)

Time: up to 12 months

Measure: Incidence of Adverse Events leading to discontinuation

Time: up to 12 months

Measure: Incidence of Serious Adverse Events (SAEs)

Time: up to 12 months

Measure: Vital signs of body temperature

Time: up to 12 months

Measure: Vital signs of blood pressure

Time: up to 12 months

Measure: Vital signs of respiratory rate

Time: up to 12 months

Measure: Number of Participants with abnormal physical examinations

Time: up to 12 months

Measure: Number of clinically significant changes in Electrocardiograms (ECGs)

Time: up to 12 months

Measure: Number of clinically significant changes in lab assessment of blood serum

Time: up to 12 months

Measure: Number of clinically significant changes in lab assessment of urine

Time: up to 12 months

Measure: Number of Clinically significant changes in lab assessment of blood

Time: up to 12 months

Measure: Maximum concentration (Cmax) of BMS-986322 in Part C

Time: up to 12 months

Measure: Time of maximum concentration (Tmax) of BMS-986322 in Part C

Time: up to 12 months

Measure: Terminal elimination rate constant (Lambda_z) of BMS-986322 in Part C

Time: up to 12 months

Measure: Terminal elimination half-life (T-Half) of BMS-986322 in Part C

Time: up to 12 months

Measure: Area under the plasma concentration-time curve extrapolated to infinity [AUC(INF)] of BMS-986322 in Part C

Time: up to 12 months

Measure: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-T)] of BMS-986322 in Part C

Time: up to 12 months

Measure: Apparent oral clearance (CL/F) of BMS-986322 in Part C

Time: up to 12 months

Measure: Apparent volume of distrubution at terminal phase (Vz/F) of BMS-986322 in Part C

Time: up to 12 months

No related HPO nodes (Using clinical trials)